Results of phase Ib EQUATE study of ALZUMAb in acute graft-versus-host disease presented at Transplantation & Cellular Therapy Meeting
Equillium announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research
The abstract highlights positive final study results, including long-term follow-up data for up to one year, from EQUATE (NCT03763318), a Phase Ib study of ALZUMAb (itolizumab) in combination with corticosteroids (CS) to treat subjects with newly diagnosed severe acute graft-versus-host disease (aGVHD). The data demonstrate promising outcomes in subjects with severe aGVHD.
Equillium has since initiated EQUATOR (NCT05263999), a Phase III study of itolizumab as a potential initial therapy for aGVHD in combination with CS. The EQUATE study is a Phase Ib/II trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of itolizumab for first-line treatment in patients who present with aGVHD (NCT03763318). The Phase Ib part of the trial is an open-label dose escalation study in adult patients who present with high-risk aGVHD and typically respond poorly to steroids. The Phase Ib data will inform selection of the dose to be used in the next phase of development for the program.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.